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Abstract
Background: Psychiatric problems have been commonly reported in patients with migraine. This study investigated
the reliability and validity of the Generalized Anxiety Disorder-7 (GAD-7) and Generalized Anxiety Disorder-2 (GAD-2) in
patients with migraine.
Methods: Subjects were recruited from a headache clinic and a neuropsychologist examined their GAD using the Mini
International Neuropsychiatric Interview-Plus Version 5.0.0 (MINI). Subjects completed several instruments, including the
GAD-7, the Beck Anxiety Inventory (BAI), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test-6
(HIT-6), and the Migraine-Specific Quality of Life (MSQoL).
Results: Among 146 participants, 32 patients (21.9 %) had GAD as determined by the MINI. Cronbach’s α for the GAD-7
and GAD-2 were 0.915 and 0.820, respectively. At a cutoff score of 5, the GAD-7 had a sensitivity of 78.1 %, a specificity
of 74.6 %, a positive predictive value (PPV) of 46.3 %, and a negative predictive value (NPV) of 92.4 %. At a cutoff score
of 1, the GAD-2 had a sensitivity of 84.4 %, a specificity of 72.8 %, a PPV of 46.6 %, and a NPV of 94.3 %. The scores
of the GAD-7 and GAD-2 well correlated with the BAI score, the MIDAS score, the HIT-6 score, and the MSQoL score.
Conclusions: The GAD-7 and GAD-2 are both reliable and valid screening instruments for GAD in patients with
migraine.
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Background
Migraine is a common and often disabling neurological
disorder. In a systemic review of population-based stud-
ies, the overall prevalence of migraine worldwide was
11 %, with prevalence rates of 6 % in males and 14 % in
females [1]. Migraine represents a public health problem
with an enormous burden to both individual patients
and society [2].
Psychiatric problems have been commonly reported in
patients with migraine. In a Korean hospital-based study,
36.3 % of patients with migraine had depression and
23.1 % revealed anxiety by self-report questionnaires [3].
In an Italian multicenter study, 23.1 % of patients with
migraine exhibited major depressive disorder (MDD)
and 18.4 % exhibited generalized anxiety disorder (GAD)
as classified by a structured interview and the Mini
International Neuropsychiatry Interview (MINI) [4].
Psychiatric comorbidity complicates the management
of patients with headache, and the prognosis for headache
treatment is poor [5]. Comorbid psychiatric disorders in
patients with migraine affect the frequency and intensity
of migraine attacks [6, 7]. In patients with episodic mi-
graine, the presence of psychiatric disorders, such as anx-
iety or depression or both, facilitate the evolution of the
headache into the chronic form [8]. Patients with mi-
graine, anxiety, and chronic depression also had poor
health-related quality of life (QOL) [9]. Among psychi-
atric disorders, anxiety is a common psychiatric comor-
bidity in patients with migraine [10–13]. Anxiety, more
than depression, predicts long-term migraine persistence,
headache-related disability and reduces perceptions of
efficacy with acute treatment [14]. Therefore, the early
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diagnosis and treatment of anxiety is important for the
proper management of patients with migraine. For these
purposes, a simple, rapid screening instrument to detect
anxiety is a prerequisite, especially in a busy clinical setting.
The Generalized Anxiety Disorder-7 (GAD-7) was
developed in the USA as a valuable screening tool for
detecting GAD in primary care patients [15]. The Gener-
alized Anxiety Disorder-2 (GAD-2) is a short version of
the tool that is composed of the first two questions of
the GAD-7 [16]. Both the GAD-7 and GAD-2 have been
widely used by general practitioners [16]. Although the
GAD-7 and GAD-2 were validated in primary care pa-
tients, their usefulness in patients with migraine is un-
known. Recently, the Patient Health Questionnaire-9
(PHQ-9) was validated for detecting a MDD in patients
with migraine [17]. However, the cutoff score of the PHQ-
9 was different from previous studies which were con-
ducted in primary care patients. Likewise the PHQ-9, it is
needed to validate the GAD-7 and GAD-2 in patients with
migraine. Therefore, this study investigated the reliability
and validity of the GAD-7 and GAD-2 as screening tools
in patients with migraine.
Methods
Subjects
Subjects in this study were new patients with migraine
who had consecutively visited a outpatients headache
clinic in the Department of Neurology at Kyungpook
National University Hospital from December 2014 to May
2015. Patients were adolescents and adults (aged 16–65
years old) who were newly diagnosed at our clinic or were
already diagnosed but had not taken triptans, preventive
medicines, or other neuropsychiatric agents within the last
month. A diagnosis of migraine was based on the Inter-
national Classification of Headache Disorders, 3rd edition,
beta version [18]. Patients were excluded if they were
unable to cooperate in the psychiatric interview or
had difficulty understanding the questionnaire because
of illiteracy, mental retardation, serious medical, neuro-
logical, or psychiatric disorders, and alcohol or drug abuse.
Patients with a probable migraine and those declining the
interview were also excluded.
Study design
A cross-sectional study was conducted as part of a
hospital-based study that examined the impact of psy-
chiatric disorders on migraine and migraine-associated
medications, such as triptans and preventive medicines.
The Institutional Review Board of Kyungpook National
University Hospital approved the study. All participants
gave written informed consent. Subject’s medical charts
were reviewed to collect demographic, social, and clinical
information for a computerized database. Sociodemo-
graphic data included age, gender, education, employment,
household income (earning at least three million KRW
per month, equivalent to 2800 USD per month or not),
and marital status (married or unmarried, divorced, and
bereaved). Clinical data included the type of migraine, age
at onset, disease duration, attack frequency, attack dur-
ation, family history, and accompanying symptoms (pres-
ence of photophobia, phonophobia, or osmophobia). A
family history of migraine was defined as an existing diag-
nosis of migraine in a lineal ascendant and/or siblings.
Photophobia, phonophobia, and osmophobia were defined
as hypersensitivity to light, sound, and certain odors
during migraine attacks that could cause avoidance of
those stimulations or aggravation of migraine symptoms.
Patients were asked whether they experienced symptoms
during the preceding year.
To measure the reliability of the GAD-7 and GAD-2
in eligible subjects, one neuropsychologist examined their
GAD using the Mini International Neuropsychiatric
Interview-Plus Version 5.0.0 (MINI) [19]. Subsequently,
patients provided several self-reported questionnaires, in-
cluding the Beck Anxiety Inventory (BAI) [20], the Korean
version of the Migraine Disability Assessment Scale
(MIDAS) [21], the Headache Impact Test-6 (HIT-6) [22],
and the Migraine-Specific Quality of Life (MSQoL) [23],
to examine the validity of the GAD-7 and GAD-2.
Interview and questionnaires
Mini International Neuropsychiatric Interview-Plus Version
5.0.0 (MINI)
The MINI-Plus 5.0.0 is an internationally validated brief
structured interview that is used extensively as a diagnos-
tic tool for psychiatric disorders from the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
and the International Classification of Diseases-10. The
reliability and validity of this instrument is well established
[24], and the Korean translation is also validated [19].
Generalized Anxiety Disorder-7 (GAD-7) and Generalized
Anxiety Disorder-2 (GAD-2)
The GAD-7 and GAD-2 were designed for use in primary
care patients [15, 16]. The GAD-7 consists of a self-report
questionnaire that allows for the rapid detection of GAD
[15]. Subjects are asked if they were bothered by anxiety
related problems over the past two weeks by answering
seven items on a 4-point scale. The total scores ranged
from 0 to 21. At a cutoff score of 9, the GAD-7 had a
sensitivity of 89 % and a specificity of 82 % for detecting
GAD compared with a structured psychiatric interview
[15]. The GAD-2 is a short version of the tool that is
composed of the first two questions of the GAD-7 [16]. At
a cutoff score of 2, the GAD-2 had a sensitivity of 86 %
and a specificity of 83 % for detecting GAD [16]. The
GAD-7 was translated into the Korean language, and was
freely downloadable on the Patient Health Questionnaire
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website (www.phqscreeners.com) [25]. The translated ver-
sion was translated back into English by a Korean English
teacher. Finally, the two versions were compared by a na-
tive English speaker who concluded that they were identi-
cal. Thereafter, we administered it to 20 Korean PWE for
the evaluation of potential problems in comprehension or
cultural differences. No further adaptations were required.
Beck Anxiety Inventory (BAI)
The BAI is a 21-item self-report measure of anxiety sever-
ity. The scale consists of 21 items, each describing a com-
mon symptom of anxiety. The respondent is asked to rate
how much he or she has been bothered by each symptom
over the past week on a 4-point scale from 0 to 3. The
following cutoff points were used: 0–21, normal; 22–26,
mild disturbance; 27–31, moderate disturbance; and
32–63, severe disturbance. The Korean version of the
BAI has been validated [20]. Those who scored more than
21 points on the BAI were considered to have anxiety
symptoms. Cronbach’s α was 0.9.
Migraine Disability Assessment Scale (MIDAS)
The Korean version of the MIDAS, a 5-item question-
naire that was designed to evaluate disability during the
previous three months, was used in this study [21].
Patients were asked to report decreased performance
in the domains of work/school, household work, and
family/social activities. Scores (0–27) measure the overall
level of disability: Grade I (0–5), Grade II (6–10), Grade
III (11–20), and Grade IV (above 21). Cronbach’s α was
0.75.
Headache Impact Test-6 (HIT-6)
The HIT-6 was developed in the United States to meas-
ure a wider spectrum of headache-induced burden [26].
Items in the HIT-6 cover several domains: pain, social
functioning, role functioning, vitality, cognitive function-
ing, and psychological distress. Each item is answered on
a 5-point Likert scale (6 = never, 8 = rarely, 10 = some-
times, 11 = very often, 13 = always). The total scores
ranged from 36 to 78; larger scores indicate a greater
impact. For interpretation, HIT-6 scores are categorized
in four groups: scores ≤49 indicate little or no impact,
scores between 50 and 55 indicate some impact, scores
between 56 and 59 indicate a substantial impact, and
scores ≥60 indicate a severe impact [27]. The Korean
version of the HIT-6 was validated and Cronbach’s α
was 0.85 [22].
Migraine-Specific Quality of Life (MSQoL)
The MSQoL developed by Wagner et al. and is a valid and
reliable tool for clinical migraine research [28]. A Korean
translation of this 25-item questionnaire has been vali-
dated [23]. The items are rated on a 4-point scale (1–4).
The total scores ranged from 25 to 100. A lower total
score indicates a poorer QOL. Cronbach’s α was 0.93.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS ver-
sion 21.0) was used for data analysis. The Med Calc 8.0
was used to perform receiver operating characteristic
(ROC) analyses to measure sensitivity, specificity, positive
predictive values (PPVs) and negative predictive values
(NPVs) for a range of cutoff scores of the GAD-7 and
GAD2 with respect to the diagnoses of GAD by the
MINI-Plus 5.0.0. Optimal cutoff scores were also com-
puted using criteria that minimize the Euclidean distance
from point (sensitivity and specificity) to point in the x-y
plane. The descriptive statistics are presented as counts,
percentages, means, and standard deviations. Independent
t-tests, Mann-Whitney U tests, and Chi-square tests
were used to compare continuous or categorical vari-
ables. Cronbach’s α was computed to ascertain internal
consistency and was recalculated after items were re-
moved. Nonparametric correlations (Spearman’s ρ) were
used to determine the validity of the GAD-7 and GAD-2.
The level of statistical significance was set at p < 0.05.
Results
Of the 207 patients who consecutively visited a headache
clinic, 61 were excluded because of probable migraine
(n = 23), taking preventive medicine for migraine or psy-
chotropic agents (n = 10), illiteracy (n = 6), age older than
70 (n = 4), and refusal to take part in the study (n = 18).
The 146 remaining patients were eligible for this study.
According to the MINI, 32 patients (21.9 %) were diag-
nosed with GAD. The relationships between GAD and
demographic, clinical, and psychosocial characteristics
are listed in Table 1. There were no significant differences
in demographic characteristics. Among clinical character-
istics, patients with GAD were more likely to have a
phonophobia; this likelihood was statistically significant.
Patients with GAD exhibited significantly higher scores on
the GAD-7, the BAI, and the HIT-6, a lower score on the
MSQoL than those without GAD.
The subjects completed the GAD-7 without any dif-
ficulties in comprehending and replying to the ques-
tions. Cronbach’s α for the GAD-7 and GAD-2 were
0.915 and 0.820, respectively, indicating excellent internal
consistency. As shown in Table 2, all of the items in the
GAD-7 were significantly and positively associated with
the total GAD-7 score, and α did not decrease if items
were deleted. The ROC analyses of the GAD-7 and GAD-
2 are shown in Table 3, and the ROC curves are illustrated
in Fig. 1. The ROC analysis of the GAD-7 exhibited an
area under the curve (AUC) of 0.849 (95 % CI = 0.775–
0.923; SE = 0.038; p < 0.001). At a cutoff score of >5, the
GAD-7 sensitivity was 78.1 % and specificity was 74.6 %,
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with a PPV of 46.3 % and an NPV of 92.4 %. The ROC
analysis of the GAD-2 exhibited an AUC of 0.842 (95 %
CI = 0.763–0.920; SE = 0.040; p < 0.001). At a cutoff score
>1, the GAD-2 sensitivity was 84.4 with a specificity of
72.8 %, a PPV of 46.6 %, and a NPV of 94.3 %.
The validity of the GAD-7 and GAD-2 are shown in
Table 4. The GAD-7 score is well correlated with the
BAI score (p < 0.001), the MIDAS score (p < 0.001), the
HIT-6 score (p < 0.001), and the MSQoL score (p < 0.001).
The GAD-2 score was also well correlated with the BAI
score (p < 0.001), the MIDAS score (p = 0.022), the HIT-6
score (p < 0.001), and the MSQoL score (p < 0.001).
Discussion
This might be the first study investigating the reliability
and validity of the GAD-7 and GAD-2 as screening in-
struments of anxiety in patients with migraine. The GAD-
7 and GAD-2 were easily comprehended and quickly
completed by patients. Furthermore, they had excellent
internal consistency reliability (Cronbach’s α =0.915 for
the GAD-7 and Cronbach’s α =0.820 for the GAD-2). The
validity of the GAD-7 and GAD-2 was determined by
correlation with scores from the BAI, the MIDAS, the
HIT-6, and the MSQoL.
Many validation studies have been conducted for pa-
tients in primary care and hospital settings. The GAD-7
and GAD-2 have been validated in different populations
and patient groups [15, 16, 29–31]. The initial validation
study for the GAD-7, conducted in primary care patients,
had a Cronbach’s α of 0.92, a sensitivity of 89 %, and a
Table 1 Demographic, clinical, and psychosocial characteristics of the eligible subjects with respect to current GAD as determined
by the MINI-Plus 5.0.0
Mean ± SD (range) or number (%)
No GAD GAD
Characteristics (n = 114) (n = 32) p value*
Age, years 40.7 ± 13.0 (16–65) 37.3 ± 12.8 (17–61) 0.195
Gender, female 101 (88.6) 25 (78.1) 0.128
Education, years 12.9 ± 2.8 (5–18) 12.8 ± 2.8 (6–16) 0.877
Job, yes 45 (39.5) 15 (46.9) 0.452
Household income, at least 3 million KRW/month 77 (67.5) 19 (59.4) 0.390
Married without divorce or bereavement 72 (63.2) 18 (56.3) 0.478
Age at onset, years 30.5 ± 12.3 (8–59) 29.1 ± 12.6 (11–54) 0.570
Disease duration, years 10.2 ± 8.3 (0–36) 8.3 ± 7.9 (1–33) 0.239
Attack frequency/3 months 16.0 ± 18.5 (1–90) 22.8 ± 24.9 (3–90) 0.160
Attack duration, hours 26.4 ± 21.8 (4–72) 30.1 ± 21.7 (4–72) 0.395
Migraine chronicity, chronic 64 (56.1) 20 (62.5) 0.520
Family history of migraine 70 (61.4) 21 (65.6) 0.663
Photophobia 49 (43.0) 18 (56.3) 0.183
Phonophobia 67 (58.8) 26 (81.3) 0.019
Osmophobia 55 (48.2) 17 (53.1) 0.626
GAD-7 score 3.7 ± 3.4 (0–15) 10.2 ± 5.4 (1–21) <0.001
BAI score 9.8 ± 7.1 (0–35) 25.3 ± 14.7 (2–56) <0.001
MIDAS, day 23.0 ± 29.3 (0–190) 36.5 ± 41.3 (0–183) 0.092
HIT-6 score 57.7 ± 7.6 (40–72) 63.9 ± 6.3 (48–78) <0.001
MSQoL 70.1 ± 15.3 (34–94) 54.8 ± 15.3 (26–85) <0.001
GAD Generalized Anxiety Disorder, MINI-Plus 5.0.0 Mini International Neuropsychiatric Interview-Plus Version 5.0.0, KRW Korean Won, GAD-7 Generalized Anxiety
Disorder-7, BAI Beck Anxiety Inventory, MIDAS Migraine Disability Assessment Scale, HIT-6 Headache Impact Test-6, MSQoL Migraine-Specific Quality of Life
*Independent t-test or chi-square tests were performed for the comparison of variables
Table 2 Corrected item-total correlations and Cronbach’s α





Item 1 0.770 0.899
Item 2 0.824 0.893
Item 3 0.772 0.900
Item 4 0.718 0.905
Item 5 0.750 0.903
Item 6 0.722 0.904
Item 7 0.659 0.911
GAD-7 Generalized Anxiety Disorder-7
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specificity of 82 % at a cutoff score of 9 [15]. In a Finnish
study that was conducted in health centers, the sensitivity
was 100 % and the specificity was 82.6 % with a cutoff
score of 7 or more [29]. In a Spanish hospital-based study,
the GAD-7 had a Cronbach’s α of 0.936, a sensitivity of
86.8 and a specificity of 93.4 % at a cutoff score of 9 [30].
In a Dutch population-based study, the GAD-7 had a
Cronbach’s α of 0.86, a sensitivity of 83 % and a specificity
of 65 % at a cutoff score of 12 or greater [31]. While the
reliability in our study is consistent with these reports, the
sensitivity was lower and the specificity was higher than
the Dutch study at the lower cutoff score [31].
The GAD-2 has not been as frequently validated as
the GAD-7. The first 2 items of the GAD-7 can be use-
ful when an ultra-brief screening tool is desired. The
initial GAD-2 validation study was conducted on pri-
mary care patients, and reported a sensitivity of 86 %
and specificity of 83 % at a cutoff score of 3 or greater
[16]. In a Finnish study that was conducted in health
centers, the sensitivity was 83 % and the specificity was
90 % with a cutoff score of 3 or more [29]. In a Dutch
population-based study, the GAD-2 had a sensitivity of
83 % and specificity of 61 % at a cutoff score of 4 or
greater [31]. In our study, the sensitivity was similar and
the specificity was lower than the Dutch study at the
lower cutoff score [31].
The cutoff scores in the validation studies of the GAD-7
and GAD-2 in several countries were different from each
other with respect to each study’s settings and language
[15, 16, 29–31]. Our study showed that at a cutoff scores
of 5 in the GAD-7 and 1 in the GAD-2 had the highest
sum of sensitivity and specificity. Cutoff scores were all
lower than in previous studies. This suggests that the
GAD-7 and GAD-2 validation should be performed for
each study settings and specific disease groups. For ex-
ample, a validation study of the GAD-7 for patients with
Table 3 The ROC analyses of the GAD-7 and GAD-2 for the diagnosis of current GAD as determined by the MINI-Plus 5.0.0
Cut off score Sensitivity Specificity PPV NPV AUC SE 95 % CI p value
GAD-7
> 3 90.6 57.0 37.2 95.6 0.738 0.045 0.651–0.826 <0.001
> 4 84.4 67.5 42.2 93.9 0.760 0.046 0.669–0.850 <0.001
> 5 78.1 74.6 46.3 92.4 0.763 0.049 0.668–0.859 <0.001
> 6 65.6 81.6 50.0 89.4 0.736 0.054 0.631–0.841 <0.001
> 7 59.4 87.7 57.6 88.5 0.735 0.056 0.626–0.845 <0.001
GAD-2
> 0 93.8 46.5 33.0 96.4 0.701 0.046 0.611–0.791 0.001
> 1 84.4 72.8 46.6 94.3 0.786 0.045 0.698–0.874 <0.001
> 2 53.1 89.5 58.6 87.2 0.713 0.058 0.600–0.826 <0.001
ROC reveiver operating characteristic, GAD-7 Generalized Anxiety Disorder-7, GAD-2 Generalized Anxiety Disorder-2, GAD Major Depressive Disorder, MINI-Plus 5.0.0










Fig. 1 Receiver operating characteristic curves of the Generalized
Anxiety Disorder-7 and Generalized Anxiety Disorder-2
Table 4 Correlation between the GAD-7 and GAD-2 scores and
the BAI score, the MIDAS score, the HIT-6 score, and the MSQoL
score











GAD-7 Generalized Anxiety Disorder-7, GAD-2 Generalized Anxiety Disorder-2,
BAI Beck Anxiety Inventory, MIDAS Migraine Disability Assessment Score,
HIT-6 Headache Impact Test-6, MSQoL Migraine-Specific Quality of Life
*Spearman correlations are applied
Seo and Park The Journal of Headache and Pain  (2015) 16:97 Page 5 of 7
epilepsy in the Korea reported that a cutoff score of 6 was
appropriate for detecting GAD [32]. Differences in the
cutoff score may also be related to different interpretations
of grading using the Likert scale according to the language
difference. For example, a rapid screening instrument for
detecting MDD in people with epilepsy, the Neurological
Disorders Depression Inventory for Epilepsy, had different
cutoff scores when it was validated in different languages
[33]. Given these possibilities, it is necessary to validate
the GAD-7 and GAD-2 according to different language.
There are several limitations in this study. First, the
sample size of the study was small. This may caused a
difference in the sensitivity and specificity compared with
other studies. Second, the GAD-7 and GAD-2 consist
of a self-report questionnaire. These screening instru-
ments only provide a probable diagnosis of GAD that
should be investigated by further evaluation. Third, with a
cutoff score of 5 in the GAD-7 and a cutoff score of 1 in
the GAD-2, the PPVs were 46.3 and 46.6 %, respectively,
which may lead to false-positive results. The GAD-7 mea-
sures anxiety related problems over the past two weeks.
However, the MINI interview investigates GAD over the
past 6 months. Because of the difference in the observa-
tion period between the two instruments, a low PPVs of
the GAD-7 and GAD-2 may exist. Fourth, the GAD-7 and
GAD-2 focus on only 1 anxiety disorder, although there
are many types of anxiety disorders that require clinical
attention. Fifth, this study validated the Korean version of
the GAD-7 and GAD-2 in Korean patients with migraine,
and their diagnostic properties may be different from
those in other languages and countries.
Conclusions
Anxiety is a common psychiatric comorbidity in patients
with migraine. Screening for anxiety in patients with mi-
graine can be an effective method to recognize previously
unidentified cases of anxiety. The GAD-7 and GAD-2 are
simple screening instruments for detecting GAD in pa-
tients with migraine. The timely identification of anxiety
in patients with migraine is important, as is proper man-
agement after diagnosis.
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